<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835235</url>
  </required_header>
  <id_info>
    <org_study_id>NN9030-4295</org_study_id>
    <secondary_id>U1111-1180-3542</secondary_id>
    <nct_id>NCT02835235</nct_id>
  </id_info>
  <brief_title>A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity</brief_title>
  <official_title>A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects With Prediabetes and With Overweight or Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America. The aim of the trial is to
      investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and
      Female Subjects being overweight or with obesity
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Day 1-112</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC9204-0530 serum concentration-time curve</measure>
    <time_frame>Day 84-112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration of NNC9204-0530</measure>
    <time_frame>Day 84-112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Day -1, Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>NNC9204-0530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation within the cohort before reaching final dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC9204-0530</intervention_name>
    <description>Administered daily subcutaneously (s.c., under the skin)</description>
    <arm_group_label>NNC9204-0530</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered daily subcutaneously (s.c., under the skin)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age between 18 and 55 years (both inclusive) at the time of signing
             informed consent

          -  Body mass index between 25.0 and 39.9 kg/m^2 (both inclusive) at screening.

        Exclusion Criteria:

          -  Haemoglobin A1c (HbA1c) equal or above 6.5%

          -  Any clinically significant weight change (above or equal to 5% self-reported change)
             or dieting attempts (e.g. participation in an organized weight reduction program)
             within the last 90 days prior to screening

          -  Any prior obesity surgery or currently present gastrointestinal implant.

          -  Abnormal ECG (electrocardiogram) results including 2nd or 3rd degree AV-block,
             prolongation of the QRS complex above 120 ms, or the QTcF interval above 430 ms
             (males) or above 450 ms (females), or other clinically relevant abnormal results, as
             judged by the investigator

          -  A history of additional risk factors for Torsades de pointes (e.g., heart failure,
             hypokalaemia, family history of Long QT Syndrome)

          -  History of pancreatitis (acute or chronic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>July 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
